AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...

The common food allergy affects around one in 50 adults in the UK but is often dismissed or assumed to be hay fever. A GP has ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

Twenty per cent of people in the UK are affected by hay fever, but GPs have warned that some people who think they are ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

There's no cure for hay fever but many people suffering symptoms like coughing, itchiness, sneezing and more may actually be ...

A 100,000-meter drill programme is currently underway at the Boundiali gold project, with a particular focus on the higher ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

The bulk sample carried an average grade of 5.72 grams per tonne (“g/t”) gold (“Au”), 0.7% above the average predicted grade ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...